TY - JOUR
T1 - Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases
AU - Van Der Heijden, M.
AU - Kraneveld, A.
AU - Redegeld, F.
PY - 2006/3/8
Y1 - 2006/3/8
N2 - Immunoglobulin free light chains were long considered irrelevant bystander products of immunoglobulin synthesis by B lymphocytes. To date, different studies suggest that free light chains may have important functional activities. For instance, it has been shown that immunoglobulin free light chains can elicit mast cell-driven hypersensitivity responses leading to asthma and contact sensitivity. Free light chains also show other biologic actions such as anti-angiogenic and proteolytic activities or can be used as specific targeting vehicles. Levels of free light chain levels in body fluids increase markedly in diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. In this review, we will focus on the unexpected biological activities of immunoglobulin free light chains with special attention to its possible role in the induction of chronic inflammatory diseases. © 2006 Elsevier B.V. All rights reserved.
AB - Immunoglobulin free light chains were long considered irrelevant bystander products of immunoglobulin synthesis by B lymphocytes. To date, different studies suggest that free light chains may have important functional activities. For instance, it has been shown that immunoglobulin free light chains can elicit mast cell-driven hypersensitivity responses leading to asthma and contact sensitivity. Free light chains also show other biologic actions such as anti-angiogenic and proteolytic activities or can be used as specific targeting vehicles. Levels of free light chain levels in body fluids increase markedly in diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. In this review, we will focus on the unexpected biological activities of immunoglobulin free light chains with special attention to its possible role in the induction of chronic inflammatory diseases. © 2006 Elsevier B.V. All rights reserved.
UR - http://www.scopus.com/inward/record.url?scp=33644746124&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2005.12.065
DO - 10.1016/j.ejphar.2005.12.065
M3 - Review article
SN - 0014-2999
VL - 533
SP - 319
EP - 326
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1-3
ER -